La Anemia de Fanconi se consideraba una enfermedad huérfana por lo poco frecuente y lo poco que se conocían sus causas, sus conexiones a otras enfermedades, y sobre la existencia de tratamientos.
An update on the international Fanconi anemia gene therapy trial
An update for families about the FA pathway and fertility
People with FA have a 500- to 700-fold increased risk of developing head and neck tumors when compared to the general population. Alternative therapeutic options are desperately needed.
To celebrate FARF’s 30th anniversary, we are asking our community to help design an original, limited edition FARF t-shirt.
More than 250 FA researchers and clinicians gathered in late 2018 to share updates in FA research and clinical care. Here are the key takeaways.